Abstract
Nucleation and metastability of the eflucimibe (S)-2‘,3‘,5‘-trimethyl-4‘-hydroxy-dodecylthiophenyl-acetanilide, a new acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitor, have been investigated according to a polythermal method. Eflucimibe exhibits two polymorphs, A and B, which crystallize simultaneously (concomitant polymorphs). The focus of this study was on the effect of the cooling rate, the initial concentration, and the seeds on metastability and polymorphism of eflucimibe. For nonseeded crystallization, it was found that the metastable zone width is large (primary nucleation) and fulfills well the linear relation between log ΔTmax and log(dT/dt). In addition, the X-ray powder diffraction and differential scanning calorimetry analyses of the powder obtained show that the desired polymorph (pure A form) is difficult to obtain. On the contrary, for seeded experiments, the metastable zone width is significantly reduced (secondary nucleation) and the occurrence of polymorphism is controlled by seeding with the desired polymorph.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
